Ultragenyx Pharmaceutical Inc. (0LIF.L)

35.75 -0.83 (-2.28%) As of 04:44PM BST. Market open.

Ultragenyx Pharmaceutical Inc.

60 Leveroni Court
Novato, CA 94949
United States
415 483 8800
https://www.ultragenyx.com

Sector(s): 
Industry: 
Full-time employees: 1,311

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Emil D. Kakkis M.D., Ph.D.	Founder, Pres, CEO & Director	1.37M	N/A	1960
Mr. John Richard Pinion II	Chief Quality Operations Officer & Exec. VP of Translational Sciences	806.19k	N/A	1966
Mr. Erik Harris	Exec. VP & Chief Commercial Officer	848.24k	N/A	1971
Mr. Theodore A. Huizenga	Sr. VP, Corp. Controller & Principal Accounting Officer	N/A	N/A	1971
Mr. Dennis Karl Huang	Chief Technical Operations Officer & Gene Therapy Operations and Exec. VP	N/A	N/A	1965
Ms. Danielle Keatley	Sr. Director of Investor Relations & Corp. Communications	N/A	N/A	N/A
Ms. Karah Herdman Parschauer J.D.	Chief Legal Officer & Exec. VP	N/A	N/A	1978
Mr. Ernie W. Meyer	Chief HR Officer & Exec. VP	N/A	N/A	1964
Mr. Thomas R. Kassberg	Chief Bus. Officer & Exec. VP	N/A	N/A	1960
Mr. Vimal Srivastava	Sr. VP of Bus. Devel. & Alliance Management	N/A	N/A	1965

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Corporate governance

Ultragenyx Pharmaceutical Inc.’s ISS governance QualityScore as of 1 September 2023 is 4. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.